Abbreviations: GEMM, Genetically engineered mouse models; HLEC, human lymphatic endothelial cells; LN, lymph node; PDX, patient-derived xenografts; BO-110, bioavailable nanoplexes of (poly)inosinic:polycytidylic acid packed with polyethyleneimine.
Clinical intervention in the cancer field has been revolutionized by the identification of (epi)genetic alterations in tumor cells as the basis for rational drug design 1, 2 . Prime example of this success is malignant melanoma, where BRAF mutations have led to the generation of inhibitors with unprecedented efficacy 3, 4 . Unfortunately, responses to BRAF blockers and other genetically-targeted agents are characteristically transient due to a plethora of mechanisms of resistance [5] [6] [7] [8] [9] . Immune checkpoint blockers (e.g. anti-PD1, -PDL1 or -CTLA4) are providing unprecedented response rates, particularly in combination with targeted therapies [10] [11] [12] [13] [14] . Nevertheless, toxicities may be limiting 10, 11, 15 , and median progression-free survival remains below 3 years 11, 16 . The field is therefore, actively seeking for alternative and more effective treatments. Rather unexplored from a therapeutic perspective (in melanoma and other tumor types) is the lymphatic system. The rationale for this approach stems from the observation that expansion of the tumoral lymphatic vasculature (neolymphangiogenesis) is one of the earliest events in the dissemination of a variety of aggressive neoplasms [17] [18] [19] . Antagonists of the interaction of lymphangiogenic ligands (i.e. VEGFC/D) with their receptors (VEGFR family members) are under evaluation in multiple diseases 17, 20, 21 . However, whether sustained therapeutic responses can be achieved with these agents has yet to be and MAPK/ERK inhibition, respectively). However, the therapeutic effects of vemurafenib were shortlived, as melanomas ultimately regained growth (Fig. 1d) . Therefore, we screened for more potent blockers of neolymphangiogenesis and metastatic dissemination. Dacarbazine/DTIC was selected as a negative control in this analysis, as an example of an alkylating agent used for decades for the treatment of metastatic melanomas (most recently for NRAS-mutated cases) but now nearly discontinued for its minimal efficacy 29 . DITC (80 mg/kg, 5 doses/week, 2 weeks) had no significant effect on luciferase emission at primary tumors or distant sites (see results for NRAS-melanomas in
Figs. S1c-d). This maintained Vegfr3-luc signal was consistent with a minimal impact of DTIC on melanoma growth (Fig. 1e ).
Once references for moderate and negative anti-lymphangiogenic compounds were set, the Vegfr Luc mice were interrogated for pathogen-activated molecular pattern (PAMP)-derivatives. These agents, and in particular, nanoplexes based on long synthetic dsRNA were attractive for their promising antimetastatic activity [30] [31] [32] [33] [34] [35] . To discard unspecific effects of BO-110 on luciferase stability, we treated cells that expressed luciferase under an unrelated (SV40) promoter, and followed bioluminiscence both in vitro and in vivo.
Importantly, BO-110 had no impact on luciferase emission in any of these models ( Fig. S2a-d ).
Instead, histological staining for standard lymphatic endothelial markers (Lyve1) demonstrated an acute abrogation of tumor-driven lymphangiogenesis by BO-110 (see representative sentinel lymph nodes in Fig. 1g ). Moreover, fluorescent-based imaging of tumor cells indicated that this potent antilymphangiogenic effect was paralleled by a striking inhibitory effect on metastatic dissemination (Fig.   1h ). Importantly, in contrast to the lymphedema reported by showed that the expression of classical lymphangiogenic ligands VEGFC and VEGFD were either non-altered or even induced, respectively (see quantifications for two melanoma cell lines in Fig. 2a ).
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In contrast, BO-110 repressed MDK mRNA expression ( Fig. 2b and secretion (Fig. 2c) (Fig. 3d ).
Regarding HLEC, and consistent with these cells uptaking BO-110 (as reflected by MDA5 activation; 
Long-term anti-metastatic effects of BO-110 in vivo prevent metastatic relapse after surgery
Collectively, the data above illustrate how the Vegfr3 Luc mice can be geared to the discovery of antilymphangiogenic factors with novel modes of action. We envision this information to be relevant for melanoma patients that appear with metastatic disease at diagnosis. Still, an additional important need in the field is to monitor (and attack) metastatic relapse after surgical excision of primary lesions.
Therefore, the Vegfr3 Luc mice were interrogated for their capacity to mimic this scenario, and thus, to serve to screen for adjuvant treatments. To this end, xenografts of human mCherry-labeled SK-Mel-147 melanoma cells were implanted subcutaneously, for surgical excision of the cutaneous lesions once systemic VEGFR3-associated bioluminescence was identified. As shown in Fig. 4a , surgery resulted in a progressive reduction in systemic Vegfr3-luc emission, indicating the requirement of tumor-derived signals to maintain distal neo-lymphangiogenesis. However, and as in the case for highly aggressive melanomas in the clinic, animals ultimately succumbed to relapsed metastases, revealed by live imaging of Vegfr3-bioluminiscence (Fig. 4b , right panels), and monitoring of tumor 8 cell burden by mCherry-fluorescence (Fig. S4) . Importantly, BO-110 (4 doses every third day, starting 4 days after surgery) prevented both the re-acquisition of lymphangiogenesis and the subsequent tumor relapse (Fig. 4a bottom panels) . Importantly, the efficacy of BO-110 was long-lasting, as 90% of animals remained tumor-free 8 months after treatment (see Kaplan Meier survival curves in Fig. 4b; p=0.0001). Together, these results emphasize the versatility of Vegfr3 Luc GEMM reporter mice for non-invasive studies of melanoma initiation and progression, as well as a tractable platform for pharmacological screening for actionable targets to prevent and attack tumor metastasis.
DISCUSSION
Drug testing and target validation in melanoma are compromised by the lack of physiological systems for non-invasive imaging of metastasis. Here we exploited immunocompetent and immunodeficient
Vegfr3
Luc knock-in mice as an in vivo screening platform for anticancer agents. Specifically, our data support these mice as a versatile resource for spatio-temporal analyses of drug response on established tumors, as well as to test for compounds able to prevent tumor formation prior or after surgical excision of cutaneous lesions. Specifically, we demonstrate the efficacy of these models with the identification of potent anti-lymphangiogenic functions of the dsRNA mimic BO-110 (see model in Together, these data have implications at various levels. In particular, this work illustrates the impact of treatments that target both cancer cells and distal lymphovascular pre-metastatic niches (as the latter may be activated very early in the metastatic process). In this context, despite recent great therapeutic advances, the melanoma field is still in need of compounds, particularly in adjuvant settings, that provide long-term responses that are not restricted to specific patient subsets 28, 43 . Preclinical studies support BO-110 and other formulations of long synthetic dsRNA as potent therapeutic agents for their ability to kill melanoma cells otherwise resistant to standard therapies 32, [36] [37] [38] . We had previously linked these effects to an IFN-independent activation of apoptosis and autophagy in tumor cells 36, 44 . The Vegfr3 Luc mice revealed now an additional level of action of dsRNA mimics as potent anti-lymphangiogenic agents. This is relevant as clinical trials with dsRNA mimics are underway in various pathologies [33] [34] [35] 38 . Moreover, finding a strategy to block VEGFR3 transcription may also be attractive from a pharmacological perspective, as to date, Finally, it should be noted that although this study focused on melanoma, the Vegfr3 Luc mice could be exploited for gene discovery and pharmacological analyses in other cancer types. The ability to compare immunocompetent and immunosuppressed backgrounds, add yet further physiological relevance to whole-body imaging of lymphangiogenesis in tumor progression and therapeutic response. surgery allow also for surrogate analyses of neo-adjuvant therapies (here also shown to be effective for BO-110 treatments).
METHODS

Mouse breeding, induction of nevi and melanomas in Vegfr3
Luc GEMM, and drug treatments in vivo. was prepared and administered at 50 mg/Kg (orally, once a day, during 3 weeks) as previously described 49 .
Non-invasive imaging of tumor growth and neo-lymphangiogenesis in vivo
Non-invasive imaging of luciferase in the Vegfr3 Luc GEMM was performed using an IVIS-SPECTRUM imaging system (Perkin Helmer, Baesweiler Germany). Animals were anesthetized with isoflurane and injected intraperitoneally with 150 mg/kg luciferin (Perkin Helmer). Sequential images were obtained after luciferin injection and the maximum light emission was determined for each animal as previously described 26 . Photons emitted from specific regions were quantified using Living Image software (Caliper Life Sciences). In vivo luciferase activity is presented in photons per second per square centimeter per steradian (radiance). All experiments with mice were performed in accordance with protocols approved by the Institutional Ethics Committee of the CNIO and the Instituto de Salud
Carlos III.
Melanoma cell xenografts, patient-derived xenografts and spontaneous metastasis assays
Xenografts of established melanoma cell lines were generated in 14-week old female Vegfr3 Luc nu/nu mice by subcutaneous implantation of 1 x 10 6 cells. Tumor growth was recorded every two days by measuring the two orthogonal external diameters using a calliper. Tumour volume was calculated using the formula (a x b 2 x 0.52). Tumors were excised and processed for histological analysis when they reached 1.5 cm 
Type I IFN blocking assays.
For type I interferon blocking assays, human IFN-β blocking antibody (Clone AF814; R&D) and its corresponding isotype (Goat IgG, R&D Systems) were used at a concentration of 0.2 µg/ml. AntiInterferon-α/β Receptor Chain 2 Antibody (IFNA2, clone MAB1155; Millipore) and its corresponding isotype (Mouse IgG2a, clone GC270; Millipore) were used at 0.1 µg/ml as suggested by the provider.
Where indicated, these reagents were added simultaneously with BO-110 to the culture media. , e t a l . , e t a l .
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, e t a l . (RIGI)  IFNA2 IFNA5 IFNB1 IFNG  IRF1 IRF2 IRF3 IRF7 ISG15 ISG20  STAT1 STAT2  IFI16 IFI27 IFI44 IFI44L IFI6 IFIT1 IFIT2 IFIT3 IFIT5  OAS1 OAS3 OASL  NFKB1 NFKBIA NFKBIE RELA RELB  CCL2 CXCL10 IL1A IL26 IL28A IL29 IL6 IL8 mRNA (Fold induction, Log2) Figure S4 . Efficacy of B0-110 as an adjuvant preventing lymphangiogenesis and metastatic relapse after surgery. Shown are representative images of Vegfr3 Luc mice implanted with mCherry-labeled SK-Mel-147 for fluorescence-based monitoring of tumor growth and relapse after the excision of the cutaneous lesions. Animals were left to recover from surgery (4 days), and then were treated for 2 weeks (4 doses) with 0.8mg/kg BO-110 (n=10 animals) or vehicle control (n=8 animals). Animals continued to be imaged at different time points after stopping treatments. Note the tumor relapse (fluorescence signal) in vehicle-treated animals that is prevented by BO-110. Vegfr3Luc emission and survival curves are shown in Fig. 4a , b, respectively. Scale, p/s/cm 2 /sr (x10 6 ). 
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